Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,861 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mental Disorders, Severe Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

NCT00491894
View directory record Official record
Conditions
Cerebral Palsy, Neurological Conditions, Mental Retardation, Sialorrhea
Interventions
Oral Glycopyrrolate Liquid
Drug
Lead sponsor
Shionogi
Industry
Eligibility
3 Years to 18 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Lakewood, Colorado • Atlanta, Georgia • Bayside, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

NCT01407094
View directory record Official record
Conditions
Depression
Interventions
Sertraline, Placebo, BupropionXL
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT02153502
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 6:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Conte Center for the Neuroscience of Depression in Late Life

NCT00576875
View directory record Official record
Conditions
Major Depression
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 4 Interventional

Comparing the Effects of Four Types of Electroconvulsive Therapy on Mood and Thinking in People With Depression

NCT00487500
View directory record Official record
Conditions
Depression
Interventions
Electroconvulsive Therapy (ECT)
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 4 Interventional Results available

Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults

NCT00183729
View directory record Official record
Conditions
Depression
Interventions
Memantine, Placebo
Drug · Other
Lead sponsor
Eric Lenze
Other
Eligibility
60 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Not applicable Interventional Results available

Adapted ACHIEVE Curriculum for Community Mental Health Settings

NCT03999892
View directory record Official record
Conditions
Obesity, Mental Disorders, Severe
Interventions
ACHIEVE
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 19, 2026, 6:01 PM EDT
Withdrawn Phase 1 Interventional

A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

NCT02633657
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Redwood City, California • St Louis, Missouri • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 19, 2026, 6:01 PM EDT
Recruiting Not applicable Interventional

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

NCT06423430
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Sham-stimulation, Active-stimulation
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
22 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Not applicable Interventional Results available

Illness Management and Recovery for Veterans With Severe Mental Illness

NCT00515671
View directory record Official record
Conditions
Schizophrenia, Schizo-affective Disorder
Interventions
Illness Management and Recovery, Problem Solving
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 1 Interventional Results available

Psilocybin-assisted CBT for Depression

NCT05227612
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin, Cognitive behavioral therapy
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Not applicable Interventional Results available

Low Field Magnetic Stimulation for Treatment Resistant Depression

NCT01944644
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active Low Field Magnetic Stimulation, Sham Low Field Magnetic Stimulation
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 3 Interventional

Lethargic Depression Study

NCT00064467
View directory record Official record
Conditions
Epilepsy, Major Depressive Disorder (MDD)
Interventions
Extended-release bupropion (HCl)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
24
States / cities
Beverly Hills, California • Sherman Oaks, California • Temecula, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 19, 2026, 6:01 PM EDT
Completed No phase listed Observational

PET Whole Body Distribution Studies Using [11C]CUMI

NCT01132872
View directory record Official record
Conditions
Depression, Major Depression, Unipolar Depression, Anxiety Disorder, Anxiety Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Not applicable Interventional

Practical Application of Accelerated iTBS for MDD

NCT06113575
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder, Recurrent Episode, Severe, Major Depressive Disorder, Recurrent, Moderate
Interventions
NeuroStar TMS
Device
Lead sponsor
Sonder Behavioral Health and Wellness
Other
Eligibility
22 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 and Theophylline in Healthy Subjects

NCT01263106
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Theophylline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study

NCT02158533
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
High Dose ALKS 5461, Low Dose ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Tucson, Arizona • Carson, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 19, 2026, 6:01 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111552
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 4 Interventional

Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)

NCT00453804
View directory record Official record
Conditions
Bipolar Disorders, Schizophrenia, Schizoaffective Disorders, Alcohol Dependence
Interventions
injectable naltrexone, oral naltrexone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2008 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 4 Interventional Results available

Vilazodone for Treatment of Geriatric Depression

NCT01608295
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone; Viibryd, Paroxetine; Paxil
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

NCT01243957
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones

NCT00562367
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cytomel (liothyronine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2007 · Synced Oct 19, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

NCT01004393
View directory record Official record
Conditions
Neoplasms, Constipation, Opioid-Related Disorders
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 19, 2026, 6:01 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression

NCT01465165
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Paul Carlson
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 19, 2026, 6:01 PM EDT